Previous close | 161.10 |
Open | 144.43 |
Bid | 156.72 x 100 |
Ask | 157.57 x 100 |
Day's range | 144.00 - 158.93 |
52-week range | 83.38 - 189.97 |
Volume | |
Avg. volume | 389,980 |
Market cap | 4.475B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | 402.41 |
EPS (TTM) | 0.39 |
Earnings date | 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 188.50 |
Details on Financial Performance and Strategic Progress
Krystal Biotech (KRYS) delivered earnings and revenue surprises of -85% and 0.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business upd